News | January 10, 2024
Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
The deal includes upfront payments, milestone payments and ongoing royalties
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
Medway setup a state-of-the-art Heart Institute in Chennai
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The company received gross proceeds of approximately US$1.7 million and net proceeds,
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Subscribe To Our Newsletter & Stay Updated
